SCHEMBL7937049

SCHEMBL7937049

CNCc1cccnc1NC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.41
CASP6 P55212 1/20 0.38
GRM5 P41594 1/20 0.37
MCL1 Q07820 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
SLC6A4 P31645 4/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A3 Q01959 3/20 0.36
LTA4H P09960 1/20 0.36
ALDH1A1 P00352 3/20 0.36
PKM P14618 1/20 0.36
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
ALOX15 P16050 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
GPR84 Q9NQS5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31509923 1.00 CYP2A6 (0.41) CYP2A6CASP6GRM5MCL1HRH3
SCHEMBL13428897 0.82 ADRA2C (0.40) CASP6GRM5ALDH1A1RAB9AHTR2A
SCHEMBL17827959 0.82 GRM5 (0.41) CASP6GRM5ALDH1A1KDM4ENPC1
SCHEMBL31510053 0.80 TRPV1 (0.41) CASP6GRM5SLC6A4SLC6A3ALDH1A1
SCHEMBL23799304 0.80 GRM5 (0.55) CASP6GRM5HRH3SLC6A4SLC6A2
SCHEMBL317954 0.80 AOC1 (0.43) CASP6GRM5ALDH1A1PDCD1CD274
SCHEMBL29907732 0.80 AOC1 (0.43) CASP6GRM5ALDH1A1PDCD1CD274
SCHEMBL317953 0.80 GRM5 (0.37) CASP6GRM5HRH3ALDH1A1KDM4E
SCHEMBL20457772 0.80 GRM5 (0.37) CASP6GRM5HRH3ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL11525180 0.80 GRM5 (0.41) GRM5ALDH1A1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040958-B2 Triazole antimicrobial derivative, pharmaceutical composition and use thereof WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2021-06-22 US disclosed
US-20190038621-A1 POSACONAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2019-02-07 US disclosed
WO-2010030967-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH LLC (US) 2010-03-18 WO disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190038621-A1 POSACONAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP3A43, ERG28, SORD CYP2A6 456/4885CASP6 2855/4885GRM5 4565/4885
US-11040958-B2 Triazole antimicrobial derivative, pharmaceutical composition and use thereof SLCO1B3, CYP3A43, GSK3B CYP2A6 1374/4885CASP6 2556/4885GRM5 4173/4885
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA CYP2A6 1684/4885CASP6 1211/4885GRM5 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.